No Data
US Stock MarketDetailed Quotes
GRI GRI BIO
Watchlist
0.764
+0.153+25.06% Close 12/01 16:00 ET
0.755-0.009-1.22%
Post 19:57 ET
0.920High0.506Low4.74MVolume
0.597Open0.611Pre Close3.64MTurnover266.12%Turnover RatioLossP/E (TTM)2.48MMarket Cap36.90052wk HighLossP/E (Static)3.25MShares0.47552wk Low1.11P/B1.36MFloat Cap310.800Historical High--Dividend TTM1.78MShs Float0.474Historical Low--Div YieldTTM67.84%Amplitude0.768Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
About GRI BIO Company
GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded in May 2009 and is headquartered in La Jolla, CA.
News
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersNexImmune (NASDAQ:NEXI) stock moved upwards by 343.1% to $10.99 during Friday's pre-market session. The market value of their outstanding shares is at $11.6 million. Altimmune (NASDAQ:ALT) stoc
GRI Bio Secures FDA Clearance for Investigational New Drug Application for Pulmonary Fibrosis Treatment
GRI Bio (GRI) said Monday that the US Food and Drug Administration has cleared its investigational new drug application for GRI-0621 for the treatment of idiopathic pulmonary fibrosis.
GRI Bio Says FDA Clears IND For GRI-0621 For Treatment Of IPF; Stock Up 19%
Paper Trade
Start
Symbol
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--